Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01646021 |
Recruitment Status :
Completed
First Posted : July 20, 2012
Results First Posted : March 1, 2017
Last Update Posted : January 19, 2018
|
Sponsor:
Janssen Research & Development, LLC
Collaborator:
Pharmacyclics LLC.
Information provided by (Responsible Party):
Janssen Research & Development, LLC
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Condition |
Mantle Cell Lymphoma |
Interventions |
Drug: Ibrutinib Drug: Temsirolimus |
Enrollment | 280 |
Participant Flow
Recruitment Details | |
Pre-assignment Details | 139 participants were randomized and treated in the ibrutinib arm and 141 participants were randomized to the temsirolimus arm. |
Arm/Group Title | Ibrutinib | Temsirolimus |
---|---|---|
Arm/Group Description | Participants received 560 milligram (mg) ibrutinib (4*140 mg capsules) by mouth once daily continuous (without interruption) self-administered home treatment during the 21 day cycle. | Participants received Temsirolimus intravenous (IV) infusion 175 mg on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each subsequent 21 day cycle. Each temsirolimus dose is infused over a 30 to 60 minute period. |
Period Title: Overall Study | ||
Started | 139 | 141 |
Treated | 139 | 139 |
Completed | 0 | 0 |
Not Completed | 139 | 141 |
Reason Not Completed | ||
Death | 77 | 83 |
Study Terminated by Sponsor | 50 | 41 |
Lost to Follow-up | 2 | 2 |
Withdrawal by Subject | 10 | 15 |
Baseline Characteristics
Arm/Group Title | Ibrutinib | Temsirolimus | Total | |
---|---|---|---|---|
Arm/Group Description | Participants received 560 milligram (mg) ibrutinib (4*140 mg capsules) by mouth once daily continuous (without interruption) self-administered home treatment during the 21 day cycle. | Participants received Temsirolimus intravenous (IV) infusion 175 mg on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each subsequent 21 day cycle. Each temsirolimus dose is infused over a 30 to 60 minute period. | Total of all reporting groups | |
Overall Number of Baseline Participants | 139 | 141 | 280 | |
Baseline Analysis Population Description |
[Not Specified]
|
|||
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 139 participants | 141 participants | 280 participants | |
<=18 years |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Between 18 and 65 years |
53 38.1%
|
54 38.3%
|
107 38.2%
|
|
>=65 years |
86 61.9%
|
87 61.7%
|
173 61.8%
|
|
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Number Analyzed | 139 participants | 141 participants | 280 participants | |
66.7 (8.68) | 67.1 (9.83) | 66.9 (9.26) | ||
Sex/Gender, Customized
Measure Type: Number Unit of measure: Participants |
Number Analyzed | 139 participants | 141 participants | 280 participants |
Female | 39 | 33 | 72 | |
Male | 100 | 108 | 208 | |
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
Number Analyzed | 139 participants | 141 participants | 280 participants |
Belgium | 7 | 10 | 17 | |
Brazil | 5 | 10 | 15 | |
Canada | 6 | 3 | 9 | |
Colombia | 3 | 4 | 7 | |
Czech Republic | 7 | 7 | 14 | |
Germany | 12 | 11 | 23 | |
Spain | 5 | 14 | 19 | |
France | 5 | 5 | 10 | |
United Kingdom | 11 | 16 | 27 | |
Hungary | 5 | 7 | 12 | |
Ireland | 2 | 1 | 3 | |
Italy | 6 | 8 | 14 | |
South Korea | 11 | 3 | 14 | |
Mexico | 1 | 1 | 2 | |
Netherlands | 2 | 0 | 2 | |
Poland | 9 | 14 | 23 | |
Portugal | 3 | 3 | 6 | |
Russian Federation | 18 | 11 | 29 | |
Sweden | 10 | 8 | 18 | |
Taiwan | 5 | 1 | 6 | |
Ukraine | 6 | 4 | 10 |
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.
Results Point of Contact
Name/Title: | Director, Clinical Research |
Organization: | Janssen-Cilag International NV |
EMail: | ClinicalTrialDisclosure@its.jnj.com |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Janssen Research & Development, LLC |
ClinicalTrials.gov Identifier: | NCT01646021 |
Other Study ID Numbers: |
CR100848 PCI-32765MCL3001 ( Other Identifier: Janssen Research & Development, LLC ) 2012-000601-74 ( EudraCT Number ) U1111-1135-6930 ( Other Identifier: Universal Trial Number ) |
First Submitted: | July 18, 2012 |
First Posted: | July 20, 2012 |
Results First Submitted: | June 2, 2016 |
Results First Posted: | March 1, 2017 |
Last Update Posted: | January 19, 2018 |